Strength Seen in Arena Pharmaceuticals (ARNA): Stock Up 5.4%

Arena Pharmaceuticals, Inc. ARNA was a big mover last session, as the company saw its shares rise over 5% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $12.60 to $15.75 in the past one-month time frame.

The company has seen one positive estimate revision in the last 30 days and the Zacks Consensus Estimate also moved higher suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday's jump can turn into more strength down the road

Currently, Arena Pharmaceuticals carries a Zacks Rank #3 (Hold).

A better-ranked stock in the same industry is Regeneron Pharmaceuticals, Inc. REGN , boasting a Zacks Rank #1(Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.

Is ARNA going up? Or down? Predict to see what others think: Up or Down

Looking for Ideas with Even Greater Upside?

Most of Zacks' investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Regeneron Pharmaceuticals, Inc. REGN: Free Stock Analysis Report
 
Arena Pharmaceuticals, Inc. ARNA: Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!